


# OPIATES IN PRISON

---

Jeffrey C. Fetter, MD



# Agenda

- Opioids in the Correctional Environment
- MAT and Corrections
- Substance Abuse Treatment in NH DOC

# Suboxone



# Suboxone: Contraband



# Suboxone Contraband



# Scale of the Problem

- In one 120 inmate unit, 80% of random drug screens are positive for Suboxone
- 90% of Contraband was Suboxone in 2016
- Price \$300 per strip
- 30-40 Contraband Cases Prosecuted per Year
- Estimate only 20% of Contraband is Intercepted
- Most Contraband Legally Prescribed to Inmate's Family
  - RSA 622:24 (Introduction of Articles)—3.5 to 7 year Class B Felony

# Inmate Culture and Drugs of Abuse

- Prison Drugs of Abuse
  - Gabapentin
  - Effexor
  - Wellbutrin
- Strong-arming (Rent)
- Lawsuits
- Packing Mules on Parole Violations
- Visiting Room
- Green Dots
- Gangs
  - BOWW
  - Gangster Disciples

# Controlling Opioid Access

- Nurse Administered Medications
- Crushed and Liquid Formulations
- Formulary
- Objective Criteria for Pain Medications
  - Observed level of function with videotape
- Disciplinary Reports
  - Diversion
  - Extraneous substance abuse
- Multidisciplinary Pain Clinic



# NH DOC PAIN CLINIC

	Morphine Sulfate Tablet Purchases	Hydrocodone/ APAP Dispensed*	Acetaminophen/ Codeine Dispensed	Tramadol Dispensed	Lyrice Dispensed	Gabapentin Dispensed
2005	N/A	36960	8420	51446	0	65760
2006	N/A	63625	18956	143560	0	93816
2007	N/A	140714	19745	23789	180	150943
2008	N/A	228137	22762	41733	210	179346
2009	33700	110301	15125	39160	1263	163547
2010	25000	48319	9915	64702	4676	162134
2011	14100	45989	6800	111970	4199	180134
2012	5330**	28419	6201	117871	8508	230434
2013	3500	24753	3891	106783	10918	238764
2014	1325	15058	3028	71672	10607	224850

# MAT In Corrections: Randomized Controlled Trials

- Australia 382 patients while in prison
  - Primary outcome was needle sharing, which declined with methadone
  - No difference in opioid positive hair
- Riker's Island 195 patients while in prison
  - Buprenorphine, methadone, placebo: equivalent re-incarceration at 3 months

# MAT in Corrections: RCTs at Release

- Riker's Island 32 men for 10 months
  - 15 of 16 control subjects re-addicted and re-incarcerated
  - 3 of 16 patients on methadone re-addicted and/or re-incarcerated
- Rhode Island 90 patients with prior methadone treatment
  - Methadone group had lower 6 month heroin use
  - No difference in treatment retention
- Baltimore 211 patients being released
  - Counseling vs. counseling + methadone vs. wait list
  - No difference in re-incarceration at 1 year

# MAT at Release 2

- Riker's Island: 34 patients for 30 days
  - Injected naltrexone: 38% relapse
  - Control: 88% relapse
- Baltimore: 211 patients
  - Connection to community care
  - Buprenorphine pre-release: 47% vs post- release 34 %

Sharma et al. 2016

- Economic Analysis of Oral Naltrexone
  - 26 RCTs
  - Pooled RR 0.81 for retention in psychosocial treatment

Adi et al 2007

# Massachusetts MATRI Program

- Injectable naltrexone at release
- Eligible offenders have graduated from intensive substance abuse treatment program
- Recovery Navigator
  - Discharge planners
  - Linkages to faith-based organizations, mentors, parole, prescribers
  - Works with patient before and after release



# MATRI

- Received Injected Naltrexone at release: 303
- Received First Injection in Community: 197 (65%)
  
- Received 12 Injections: 11 (4%)
- Engaged in other treatment at 1 year: 34 (11%)

As of October, 2017

# Vermont DOC

- Buprenorphine continued for first 120 days of incarceration
- Benefits unclear
  - No disciplinary data available
  - Increasing duration to 120 days: No change in recidivism
- Costs
  - Diversion: Massive diversion problems: special unit developed



# NH DOC Substance Abuse Treatment

- Intensive Outpatient
  - Targets General Population and Close Custody Units
- Individual Counseling
  - Counselors moved from Programs to Medical & Forensic Services
- FOCUS Unit
  - Therapeutic Community
  - Diversion from Restricted Housing
  - Phases and Reinforcement
- Medication Assisted Treatment
  - Oral Naltrexone
  - Injected Naltrexone (Vivitrol) for Release





# NH DOC Medication Assisted Treatment Process

- Criteria
  - Substance use disorder
  - Commitment to treatment
  - Commitment to abstinence
  - Psychosocial treatment is not enough
- Process
  - LADC Referral
  - Mental Health Evaluation
  - Medical Evaluation
  - Collaborate with Community Corrections for release planning

# NH DOC Oral Naltrexone Program

- Total patients started Naltrexone: 47
- Completed >6 months tx in prison: 4%
- Discontinued before 6 months 34%
- Paroled out on naltrexone: 38%
- Still on Naltrexone (but not yet 6 months): 23%
  
- Of those who started Naltrexone
  - Any positive urine for opiates 34%
  
- Of those paroled
  - Switched to buprenorphine: 50%



# Vivitrol Release Program

- Received injection in prison 2016-present: 7
- Received 2<sup>nd</sup> and 3<sup>rd</sup> shot in community: 28%
- Received 4<sup>th</sup> shot: 0
  
- Positive urine during parole 57%
- Parole violation 28%



# Lessons Learned

- Transitions to Parole Need Special Attention
  - Recovery Navigators?
- MAT Entry Criteria
  - 6 months in Groups vs. Clinical Judgement
  - Risk of overdose
- Soft Benefits of MAT
  - Shorter term goal
  - Signifier of commitment
  - Connection to community treatment--bridge to buprenorphine
  - Hope